IOncology

Editor's Note: In this exclusive interview, we speak with Dr. Anna Dorothea Wagner, a leading expert in gastrointestinal oncology, about the evolving landscape of virtual targeted diagnosis and treatment for…

In 2023, significant progress has been made in the field of breast cancer research. Dr.  Zefei Jiang from The Fifth Medical Center of  Chinese PLA General Hospital shared his insights and research findings at several important conferences. This article delves into Professor Jiang's speeches, exploring the key advancements in breast cancer treatment in 2023.

Editor's note: The LAPIS Phase 3 trial was a large-scale, global, double-blind, placebo-controlled study designed to assess the efficacy of pamrevlumab in combination with chemotherapy for patients with locally advanced…

On July 14, to mark the 40th anniversary of Yunnan Cancer Hospital, the "8th Yunling Breast Cancer Summit Forum," hosted by the Yunnan Anti-Cancer Association and the Chinese Medical Education Association, was held in Kunming. The event gathered cutting-edge advances in breast cancer from domestic and international experts. Dr. Qianjun Chen from Guangdong Provincial Hospital of Traditional Chinese Medicine delivered a keynote report on "Consensus and Controversies in Anti-HER2 Therapy for HER2-Positive Breast Cancer." "Oncology Frontier" interviewed Professor Chen on site to share insights on the consensus and controversies in anti-HER2 therapy for HER2-positive breast cancer, guiding multidisciplinary collaboration to optimize patient management strategies, extend patient survival, and improve quality of life.

The CALYPSO study offers valuable insights into the effectiveness of durvalumab (PD-L1 inhibitor) plus savolitinib (MET inhibitor) (D+S) in MET-driven advanced papillary renal cancer (aPRC). At 41 months follow-up, MET-driven…

The TOPAZ-1 study has provided valuable insights into the role of plasma circulating tumor DNA (ctDNA) testing in detecting clinically actionable alterations (CAAs) in advanced biliary tract cancer (BTC). While…

At SABCS 2024, Dr. Matteo Lambertini shared insights from a major international study examining the role of risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO) in young BRCA carriers with breast cancer. The study, which analyzed data from 5,290 patients across 109 centers worldwide, offers a deeper understanding of how these surgeries impact long-term survival.

At SABCS 2024, Professor Ian Kunkler presented the 10-year results of the SUPREMO trial, a phase III study evaluating the role of postmastectomy radiotherapy (PMRT) in intermediate-risk breast cancer. The trial aimed to determine whether PMRT improves overall survival in patients with 1-3 positive lymph nodes or high-risk node-negative disease.

At SABCS 2024, Dr. Icro Meattini presented a preplanned interim analysis of the EUROPA trial, a randomized phase III study comparing exclusive endocrine therapy (ET) vs. radiation therapy (RT) in women aged 70+ with luminal-like early breast cancer. The study aimed to evaluate quality of life (HRQOL) and ipsilateral breast tumor recurrence (IBTR) to guide treatment decisions in this patient population.